Tepezza vs Tyrvaya
A side-by-side look at two eye health medications advertised on TV. Informational only — not medical advice.
| US Tepezza | US Tyrvaya | |
|---|---|---|
| Generic name | teprotumumab | varenicline nasal spray |
| Drug class | IGF-1R Inhibitor (Biologic) | Nicotinic Acetylcholine Receptor Agonist (Nasal) |
| Treats | Thyroid eye disease | Dry eye disease |
| Category | Eye Health | Eye Health |
| Manufacturer | Amgen | Viatris |
| Year approved | 2020 | 2021 |
| FDA warning | Moderate warnings | No boxed warning |
| Est. TV ad spend | — | — |
| Common side effects | Muscle spasms, Nausea, Hair loss, Hearing problems | Sneezing, Cough, Throat irritation, Nose irritation |
Frequently asked questions
Is Tepezza or Tyrvaya better?
Neither is universally "better." Tepezza (teprotumumab) and Tyrvaya (varenicline nasal spray) are both used for eye health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Tepezza and Tyrvaya?
Tepezza is a IGF-1R Inhibitor (Biologic) made by Amgen, while Tyrvaya is a Nicotinic Acetylcholine Receptor Agonist (Nasal) made by Viatris. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Tepezza has the larger estimated TV advertising budget of the two.